Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
December 2013—Skuldtech, a genomic biomarker company, has secured EUR 1 million in funding from Bpifrance (French public financing structure) as part of a project on Alzheimer disease that has received funding of EUR 8.6 million in total. The program is scheduled to last four years, with the first results expected in 2018.
December 2013—BioTheranostics announced that Mayo Clinic and Mayo Medical Laboratories will offer the company’s CancerType ID molecular cancer classification test to aid in the management of patients with metastatic cancer.
December 2013—Novartis announced a definitive agreement to sell its blood transfusion diagnostics unit to Grifols for $1.675 billion. The transaction is expected to be completed in the first half of 2014.
December 2013—Microbiologics, a St. Cloud, Minn.-based company, has acquired Phthisis Diagnostics. Phthisis’ innovative, patented G-Sphere molecular standards product line will be the foundation for Microbiologics’ move into molecular products and a new division it is forming. G-Sphere standards are synthetic genes that provide controls for virtually any organism or molecular assay.
December 2013—Transgenomic has entered into a collaborative agreement with PerkinElmer to market and distribute Transgenomic’s oncology diagnostic test portfolio of products in territories outside the United States.
December 2013—Myriad Genetics launched a new prognostic test, Myriad myPlan Lung Cancer, for patients diagnosed with early stage lung adenocarcinoma. MyPlan Lung Cancer is an RNA expression panel of 31 cell-cycle-progression genes in combination with tumor staging information to determine a patient’s risk of dying from lung cancer within five years.
December 2013—Illumina announced the launch of its TruGenome Undiagnosed Disease Test provided by the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory. This new service uses whole genome sequencing to assist physicians in identifying the underlying genetic cause of a rare or undiagnosed disease.
December 2013—Bio SB, a molecular pathology company based in Santa Barbara, Calif., announced the launch of its Bcl-6 rabbit monoclonal antibody for in vitro diagnostic use. Bcl-6 is a transcriptional regulator gene that codes for a 706-amino-acid nuclear zinc finger protein.
December 2013—Quest Diagnostics now offers BRCAvantage, a suite of four lab-developed genetic tests that identify mutations in BRCA1 and BRCA2 genes. The BRCAvantage test is performed using next-generation sequencing and multiplex ligation-dependent probe amplification to detect all published deleterious mutations in BRCA1 and BRCA2.
The Legato 110 DRS (dual-rate syringe) pump system offers researchers complete flexibility to start two pumps simultaneously for delivery of two independent flow rates.
